Literature DB >> 19568652

Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles.

César Sánchez1, Aaroa P Salas, Alfredo F Braña, Martina Palomino, Antonio Pineda-Lucena, Rodrigo J Carbajo, Carmen Méndez, Francisco Moris, José A Salas.   

Abstract

We report the generation of novel glycosylated indolocarbazoles by combinatorial biosynthesis, and the identification of two novel potent and selective compounds inhibitors of JAK2 and Ikkb kinases.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19568652     DOI： 10.1039/b905068j

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  19 in total

Review 1.  Total (bio)synthesis: strategies of nature and of chemists.

Authors:  Alexandra A Roberts; Katherine S Ryan; Bradley S Moore; Tobias A M Gulder
Journal:  Top Curr Chem       Date:  2010

Review 2.  Metabolic engineering for the production of natural products.

Authors:  Lauren B Pickens; Yi Tang; Yit-Heng Chooi
Journal:  Annu Rev Chem Biomol Eng       Date:  2011       Impact factor: 11.059

3.  Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Roberto Sanchez; Ethan A Swartz; Andrew F Stewart; Robert J DeVita
Journal:  J Med Chem       Date:  2018-08-21       Impact factor: 7.446

4.  Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.

Authors:  Kunal Kumar; Peter Man-Un Ung; Peng Wang; Hui Wang; Hailing Li; Mary K Andrews; Andrew F Stewart; Avner Schlessinger; Robert J DeVita
Journal:  Eur J Med Chem       Date:  2018-08-22       Impact factor: 6.514

Review 5.  Engineering microbial factories for synthesis of value-added products.

Authors:  Jing Du; Zengyi Shao; Huimin Zhao
Journal:  J Ind Microbiol Biotechnol       Date:  2011-04-28       Impact factor: 3.346

6.  Biosynthesis of Violacein, Structure and Function of l-Tryptophan Oxidase VioA from Chromobacterium violaceum.

Authors:  Janis J Füller; René Röpke; Joern Krausze; Kim E Rennhack; Nils P Daniel; Wulf Blankenfeldt; Stefan Schulz; Dieter Jahn; Jürgen Moser
Journal:  J Biol Chem       Date:  2016-07-27       Impact factor: 5.157

Review 7.  Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Authors:  Breland Smith; Federico Medda; Vijay Gokhale; Travis Dunckley; Christopher Hulme
Journal:  ACS Chem Neurosci       Date:  2012-08-28       Impact factor: 4.418

Review 8.  The NFκB pathway: a therapeutic target in glioblastoma.

Authors:  Lorena Nogueira; Patricia Ruiz-Ontañon; Alfonso Vazquez-Barquero; Francisco Moris; Jose L Fernandez-Luna
Journal:  Oncotarget       Date:  2011-08

Review 9.  Molecular insights on the biosynthesis of antitumour compounds by actinomycetes.

Authors:  Carlos Olano; Carmen Méndez; José A Salas
Journal:  Microb Biotechnol       Date:  2010-11-18       Impact factor: 5.813

10.  Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.

Authors:  Kunal Kumar; Peng Wang; Jessica Wilson; Viktor Zlatanic; Cecilia Berrouet; Susmita Khamrui; Cody Secor; Ethan A Swartz; Michael Lazarus; Roberto Sanchez; Andrew F Stewart; Adolfo Garcia-Ocana; Robert J DeVita
Journal:  J Med Chem       Date:  2020-02-19       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.